Experts Video Reports: Breast Cancer track

Learn about key results illustrated by slides from the sessions!

Breast Cancer track 2022.
The selection of study results covered in this track is exclusively under the responsibility of ESMO and the speakers selected by ESMO.

Expert Video Report on advances in the management of HER2-negative and HER2-low advanced breast cancer from ASCO 2022

Reporting from ASCO 2022 Annual Meeting in Chicago, Nadia Harbeck discusses the practice changing results from DESTINY-Breast04 testing trastuzumab deruxtecan vs physician's choice of treatment in HER2-low metastatic Breast Cancer, including safety profile data. She also comments the interesting results from the TROPiCS-02 trial testing sacituzumab govitecan vs physician's choice of treatment in HR-positive/HER2-negative pre-treated advanced Breast Cancer.

ESMO 2021 Expert Video Report on HER2-positive early breast cancer

Reporting from the ESMO Congress 2021, Valentina Guarneri provides an overview of the meta-analysis data in HER2-positive early breast cancer from the neoadjuvant trastuzumab-lapatinib studies with regard to the risk of relapse and death and the optimal treatment duration of adjuvant trastuzumab. She also explores the prognostic value of immune gene-expression signatures and TILs to predict the pathological response and patient outcomes.

ESMO 2021 Expert Video Report on HER2-positive metastatic breast cancer

Reporting from the ESMO Congress 2021, Cristina Saura describes the outstanding results from the DESTINY-Breast03 study and the promising results from the TULIP trial. She explains the practice changing results in both response and PFS with trastuzumab deruxtecan, and elaborates on emerging opportunities for pre-treated patients with trastuzumab duocarmazine.

#ESMO20 Expert Video Report on on atezolizumab in upfront treatment of TNBC

Reporting from the ESMO Virtual Congress 2020, Joseph Gligorov features important findings from TNBC studies elaborating advances of neoadjuvant immunotherapy in early-stage disease, and testing first-line immunotherapy in the metastatic setting.

Besides covering Impassion 031 in early TNBC, he discusses also the results from the IMpassion130 and IMpassion131 trials in unresectable locally advanced or metastatic disease, which proved to be very different despite an apparently similar study design.

#ESMO20 Expert Video Report on CDK4 6i in the adjuvant treatment of breast cancer

Reporting from ESMO Virtual Congress 2020, Stephen Johnston features the results from the monarchE study on abemaciclib and from the PALLAS trial with palbociclib, as adjuvant treatment in patients with HR positive HER2 negative early Breast Cancer.
He elaborates possible reasons why outcome in these trials was very different, and insists on the importance of risk factors assessment, as well as management of adverse events to improve treatment compliance.

Expert video report on breast cancer biomarkers from ASCO 2020

Reporting remotely on findings presented at ASCO 2020 Virtual Meeting, Thomas Bachelot comments on biomarker findings from breast cancer studies.

Expert video report on triple negative breast cancer from ASCO 2020

Reporting remotely on findings presented at ASCO 2020 Virtual Meeting, Javier Cortes comments on study results in neoadjuvant triple negative breast cancer setting.

Expert Video Report on Novel Drugs for HER2+ Advanced Breast Cancer: Focus on Brain Metastases

Reporting remotely on findings presented at ESMO Breast Cancer Virtual Meeting 2020, Guy Jerusalem comments on practice changing studies in pretreated patients with HER2+ advanced breast cancer, focusing on the important risk of brain metastasis in this population.

Expert video report on Breast Cancer from AACR 2020

Reporting remotely on findings presented at AACR 2020 Virtual Meeting, Lajos Pusztai comments on important breast cancer studies.

ESMO Congress 2019: Expert video report on breast cancer

Reporting from ESMO Congress 2019, Javier Cortes comments on positive studies in Breast Cancer that showed clinically relevant benefits. The results from MONALEESA-3 in HR+/HER2- postmenopausal breast cancer patients are further supportive for integration of CDK 4/6 inhibitors in combination with hormonal therapy in clinical practice. In early triple negative breast cancer (TNBC), KEYNOTE-522 demonstrated a benefit in response rate and showed a positive trend in terms of event-free survival with immunotherapy combined with chemotherapy in both neo-adjuvant and adjuvant treatments.

ASCO 2019: Expert video report on breast cancer

F. André reports on study results presented on breast cancer at ASCO 2019. He reports on the clinically significant results from the MONALEESA-7 trial, on results from the SOPHIA trial that tested a new antibody in patients with HER2-positive disease who present with genetic polymorphisms, and results from the NALA trial with interesting data in terms of delaying and preventing brain relapse.

AACR 2019: Expert Video Report on Liquid Biopsy

Reporting from AACR 2019 in Atlanta, F-C. Bidard comments on clinical utility of CTCs and ctDNA as biomarkers based on the results from two studies in breast and prostate cancer.

Track 2018: Videos reports from ESMO Congress and ASCO conference

Expert Video Report on the Management of Advanced Breast Cancer

Commenting on the findings from IMpassion130 and SOLAR-1 trials presented at ESMO 2018 Congress, Dr. Alessandra Gennari says that these two important study results will change the treatment of advanced breast cancer.
In conclusion, Dr Gennari remarks that the IMpassion130 study shows that we can improve the prognosis of metastatic triple negative breast cancer with immunotherapy, while the SOLAR-1 points out to a new Pi3K inhibitor alpelisib in ER-positive, HER2-negative disease and which appears to be less toxic than previously developed Pi3K compounds.

ESMO 2018 Congress: Highlights in HR-positive, HER2-negative advanced breast cancer LBA2_PR

Dr. Massimo Cristofanilli reports on key results from ESMO 2018 Congress: LBA2_PR: Overall survival with palbociclib plus fulvestrant in women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Analyses from PALOMA-3.

ESMO 2018 Congress: Highlights in Early Stage HER2+ Breast Cancer Prevention of Cardiotoxicity

Prof. Giuseppe Curigliano reports on key results on prevention of cardiotoxicity from ESMO 2018 Congress: 192PD: Randomized Trial of Lisinopril or Carvedilol for the Prevention of Cardiotoxicity in Patients with Early Stage HER2-Positive Breast Cancer Receiving Trastuzumab.

ESMO 2018 Congress: Highlights in metastatic triple negative breast cancer LBA1 PR

Dr. Peter Schmid reports on key results from ESMO 2018 Congress: LBA1_PR: IMpassion130: Results from a global, randomised, double-blind, phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in treatment-naive, locally advanced or metastatic triple-negative breast cancer.

Perspectives from ASCO 2018: Early breast cancer: The PERSEPHONE study

Helena Earl reports the results from the PERSEPHONE study that she presented at ASCO 2018 in over 4,000 patients with HER2-positive early breast cancer. It is a non-inferiority trial designed to check if the standard 12 months of adjuvant trastuzumab treatment could be reduced to 6 months with comparable disease-free survival at 4 years.

Perspectives from ASCO 2018: Advances in early breast cancer: The TAILORx trial

Joseph Sparano reporting from ASCO 2018, explains that the clinical goal in designing the TAILORx trial was to integrate information from the 21-gene assay in the treatment algorithm, and learn if chemotherapy should be given with adjuvant endocrine therapy in women with HR-positive, HER2-negative, node-negative breast cancer with mid-range Recurrence Score (RS).